European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Pharmacogenomics Hub in a strengthened IMGGE

Descripción del proyecto

Introducción de la farmacogenómica en la práctica clínica

Solo en Europa, las reacciones adversas a los medicamentos matan a cientos de miles de pacientes cada año. Por ello, el desarrollo de la farmacogenómica (PGX, por sus siglas en inglés) para personalizar terapias a fin de mejorar los resultados de los tratamientos es de gran importancia. El proyecto PharmGenHUB, financiado con fondos europeos, respaldará el esfuerzo de varios socios universitarios, coordinados por el Instituto de Genética Molecular e Ingeniería Genética de la Universidad de Belgrado (Serbia), para desarrollar diagnósticos de PGX, educación y formación, y para convertir el conocimiento sobre PGX en soluciones digitales destinadas a aplicaciones médicas en la región de los Balcanes Occidentales. El proyecto empleará secuenciación de ADN de alto rendimiento para identificar pares de marcadores PGX-fármaco específicos de los Balcanes Occidentales y diseñar herramientas electrónicas para la personalización del tratamiento en la práctica clínica.

Objetivo

Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In Western Balkans (WB), individualization of therapy is done sporadically. IMGGE (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia) is a pioneer in the PGX in WB. PharmGenHUB will strengthen IMGGE’s PGX R&I potential by exchanging knowledge between IMGGE and EU partnering institutions: University of Patras, Greece (UPAT), University of Ljubljana, Slovenia (UL), University of Trieste, Italy (UNITS). Through collaboration and knowledge sharing with 3 EU partners, IMGGE will become WB central place for PGX diagnostics and R&I, education and trainings, and translation of PGX knowledge into clinically applicable digital solutions. IMGGE’s research project, high-throughput DNA sequencing of WB populations, with support of UPAT and UL, will identify WB specific drug-PGX marker pairs and enable design of electronic tool for better decision-making in clinical practice, electronic PGX assistant for WB (ePGA-WB). iPSC model for validation of novel PGX markers relevant for Europe will be introduced at IMGGE with support of UNITS. IMGGE will renew, reinforce and establish new connections through networking with WB institutions. Project will be realized through short-term visits of IMGGE staff to EU partner institutions, staff exchanges, on-site trainings, experimental laboratory work. Outreach activities will include PGX days, WB conference and joint summer schools. To strengthen research management capacities and administrative skills of IMGGE staff, a research management unit will be established with assistance from UPAT. As focal point of PGX translational research, IMGGE will impact on WB health-care cost benefits and facilitate WB integration to EU-PGX research area through R&I activities and digitalization.

Coordinador

INSTITUT ZA MOLEKULARNU GENETIKU I GENETICKO INZENJERSTVO
Aportación neta de la UEn
€ 723 750,00
Dirección
VOJVODE STEPE 444A
11010 Beograd
Serbia

Ver en el mapa

Región
Србија - север Београдски регион Београдска област
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 723 750,00

Participantes (3)